Evidence map›Paper›PMID 42665714›Full record

ArticleProtoplasma2026

Esculetin induces apoptosis and functional impairment in INS-1 pancreatic β-cells associated with ER stress and MAPK/JNK signaling.

Ayse Karatug Kacar

Abstract read
PubMed Publisher
In one paragraph

Article in Protoplasma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ayse Karatug KacarFaculty of Science, Department of Biology, Istanbul University, Vezneciler, Istanbul, 34134, Türkiye. akaratug@istanbul.edu.tr.ORCID http://orcid.org/0000-0001-6032-470X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esculetin, a coumarin derivative, exhibits diverse biological activities; however, its impact on pancreatic β-cell stress responses and survival remains poorly defined. In this study, we investigated the effects of esculetin on cellular stress signaling, apoptosis, and functional gene expression in INS-1 pancreatic β-cells. Following treatment with 3000 µM esculetin for 6 h, cell viability, proliferation, apoptosis, oxidative stress, endoplasmic reticulum (ER) stress markers, MAPK signaling components, cell cycle distribution, and β-cell-specific gene expression were assessed. In silico molecular docking was performed to explore putative interactions between esculetin and proteins involved in ER stress, MAPK signaling, and apoptosis. Treatment with 3000 µM esculetin for 6 h increased apoptotic cell death by approximately 32-fold and elevated total oxidation status and oxidative stress index. Intracellular insulin, Ca²⁺, and CA19-9 levels were increased, accompanied by cell cycle arrest characterized by G0/G1 phase accumulation and a reduction in the G2/M population. Expression of ER stress sensors ATF6, IRE1α, and CHOP was upregulated, whereas PERK expression was reduced. In parallel, MAPK/JNK pathway activation was evidenced by increased levels of p-ATF2, p-c-Jun, and HSP90, along with decreased p-Elk1. Gene expression analysis revealed marked downregulation of β-cell functional and identity-associated genes, including Ins1, Ins2, IR, Akt, MafA, Nkx6.1, Pdx1, NeuroD1, and Pax6, while FoxO1 expression was upregulated. Collectively, these findings suggest the involvement of ER stress-associated MAPK/JNK signaling in esculetin-induced apoptosis and functional impairment in INS-1 pancreatic β-cells, providing mechanistic insight into stress-associated β-cell dysfunction.

Indexed as

ApoptosisER stressEsculetinMAPK/JNK signallingPancreatic β-cells

Identifiers

PMID42665714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.